EMEA-001531-PIP01-13-M04 - paediatric investigation plan

tasimelteon
PIPHuman

Key facts

Invented name
  • Hetlioz
  • Hetlioz
Active Substance
tasimelteon
Therapeutic area
Neurology
Decision number
P/0215/2018
PIP number
EMEA-001531-PIP01-13-M04
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of non-24-hour sleep-wake disorder in the totally blind
Route(s) of administration
Oral use
Contact for public enquiries

Vanda Pharmaceuticals Ltd

E-mail: gunther.birznieks@vandapharma.com 
Tel. +1 2027 343416

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page